ArticlePharmaceuticals (Basel, Switzerland)2023
Cannabidiol and Minor Phytocannabinoids: A Preliminary Study to Assess Their Anti-Melanoma, Anti-Melanogenic, and Anti-Tyrosinase Properties.
Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 27 citations in OpenAlex.
- Tyrosinase Inhibitors With Enhanced Potency in Mammalian and Vertebrate Models, N-(2-Mercaptoethyl)benzamide Derivatives: Design, Synthesis, and Evaluation.Chemical biology & drug design · 2026Article
- The Relationship Between (Endo)cannabinoids, the Microbiome and Melanoma.Pharmacology research & perspectives · 2026Review
- Article
- Antitumor Activity of Cannabinoids and Their Interaction with Chemotherapy: A Systematic Review and Meta-Analysis of Preclinical Evidence.Pharmaceuticals (Basel, Switzerland) · 2026Article
- THC and CBD Induce Heme Oxygenase-1-Dependent Cell Death and Trigger Mitochondrial Dysfunction in Human Melanoma and Cutaneous Squamous Cell Carcinoma Cells.Antioxidants (Basel, Switzerland) · 2026Article
- Hemp (International journal of molecular sciences · 2026Review
- Skin-Whitening Effects of Cannabinol (CBN) Through Melanin Inhibition in B16F10 Melanoma Cells.International journal of molecular sciences · 2025Article
- Cannabichromene, a key non-psychotropic phytocannabinoid in treatment of major depressive disorder: in silico and in vivo explorations.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Natural protection against oxidative stress in human skin melanocytes.Communications biology · 2025Review
- Cannabidiol in Skin Health: A Comprehensive Review of Topical Applications in Dermatology and Cosmetic Science.Biomolecules · 2025Review
- Cannabidiol-Based Thiosemicarbazones: A Preliminary Study Evaluating Their Anti-Tyrosinase Properties.Molecules (Basel, Switzerland) · 2025Article
- Exploring Cannabidiol (CBD) and Cannabigerol (CBG) Safety Profile and Skincare Potential.International journal of molecular sciences · 2024Article
- The Potential of Cannabichromene (CBC) as a Therapeutic Agent.The Journal of pharmacology and experimental therapeutics · 2024Review
- Genotoxicity of selected cannabinoids in human lymphoblastoid TK6 cells.Archives of toxicology · 2024Article
- Production of Biopolymeric Microparticles to Improve Cannabigerol Bioavailability.Materials (Basel, Switzerland) · 2024Article
- Cheungsam Seed Husk Extract Reduces Skin Inflammation through Regulation of Inflammatory Mediator in TNF-α/IFN-γ-Induced HaCaT Cells.Plants (Basel, Switzerland) · 2024Article
- Comprehensive Insight into Cutaneous Application of Hemp.Pharmaceutics · 2024Review
- Spent Material Extractives from Hemp Hydrodistillation as an Underexplored Source of Antimicrobial Cannabinoids.Antibiotics (Basel, Switzerland) · 2024Article
- Bipiperidinyl Derivatives of Cannabidiol Enhance Its Antiproliferative Effects in Melanoma Cells.Antioxidants (Basel, Switzerland) · 2024Article
- Spray-Dried Powder Containing Cannabigerol: A New Extemporaneous Emulgel for Topical Administration.Pharmaceutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Currently, there is an increased interest from both scientists and consumers in the application of cannabis/hemp/phytocannabinoids in skin-related disorders. However, most previous investigations assessed the pharmacological properties of hemp extracts, cannabidiol (CBD), or tetrahydrocannabinol (THC), with very few studies focusing on minor phytocannabinoids from hemp. In this context, the current work explored the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.